Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;15:87–97. doi: 10.2147/DDDT.S269029

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Roflumilast reduces the Doxorubicin-induced release of creatine kinase-muscle/brain (CK-MB) and cardiac troponin (cTnI). Cells were treated with 5 μmol/l Doxorubicin in the presence or absence of Roflumilast (2.5, 5 μM) for 24 hours. (A) The release of CK-MB; (B) The release of cTnI (****P<0.0001 vs vehicle control; ^{##, ###}P<0.01, 0.001 vs Doxorubicin treatment).